Search results

The purpose of this study is to unearth the factors influencing the scope and acceptability of E‐detailing concepts recently started by domestic as well as multinational companies in India.

The objective is to capture views of pharmaceutical company personnel about E‐detailing to understand factors influencing acceptance and execution of E‐detailing as a marketing communication tool. This study is based on primary data collected from the Delhi/NCR area of India. To analyze the data, an attempt is made to identify latent factors that influence various measurable characteristics. Gonzalez and Bello's approach is used in factor analyzing the responses to identify prominent influencing factors behind the adoption of E‐detailing by pharmaceutical companies.

As viewed by the company personnel, managerial readiness, operational capabilities, audience acceptance and market accessibility are the most important factors responsible for proper acceptability of E‐detailing program. Other motivators are convenience mode of communication, brand acceptance in the market, a deep relationship development with target physicians. This has a positive impact on the profit curve of the companies.

Results from this study will help pharmaceutical companies operating in India to understand factors influencing scope and acceptability of E‐detailing as an important marketing communication tool. Pharmaceutical companies may chart their strategic communication roadmap in line with the same.

In this paper, we have identified factors responsible for acceptance and execution of E‐detailing as a pharmaceutical marketing communication tool. These factors may be tested in different countries and intensity may be analyzed beyond country boundaries.

Electronic detailing (e‐detailing) has been introduced in the last few years by the pharmaceutical industry as a new communication channel to promote pharmaceutical products to physicians. E‐detailing means using digital technology: internet, video conferencing, and interactive voice response. Because of the rapid adoption of e‐detailing among physicians and because of the potential effects of e‐detailing on the physician prescribing behavior, it is important to summarize research about e‐detailing. The purpose of this article is to review the literature on e‐detailing of pharmaceuticals to physicians.

A review of the literature was conducted to address reasons behind e‐detailing emergence, e‐detailing as a replacement for traditional detailing, different definitions of e‐detailing, e‐detailing processes, the prevalence of e‐detailing among physicians, types of e‐detailing, drivers for e‐detailing adoption among physicians, and adopters' characteristics.

Based on the literature review, there are two types of e‐detailing: interactive (virtual) and video. Several factors including convenience, quality of information, and incentives are common reasons for physicians' adoption of e‐detailing. E‐detailing adopters are more likely to be residents, younger, primary care physicians, practicing in rural areas, and working in solo practice.

This paper provides timely review about e‐detailing for pharmaceutical industry practitioners and institutional healthcare policy makers. However, well designed research studies on the effects of e‐detailing on prescribing are needed. From the pharmaceutical companies perspective, more research should be conducted to determine the best ways to maximize the value pharmaceutical companies can gain through the utilization of e‐detailing tools.

The purpose of this paper is to use results from a comprehensive analysis of a physician‐prescribing model to draw guidelines on how to promote a new drug in the presence of competing older drugs, in a chronic therapeutic state.

The authors use an extensive database from SDI Health, LLC, and a second data set from IMS Health. They calibrate their model using logarithmic regression methodology. The dependent variable in the model is number of new prescriptions and the explanatory variables are physician and patient characteristics, and marketing variables.

The authors' estimates imply that heavy prescribers are likely to be specialists, be in solo practice, have more experience, receive more sales rep traffic, have more HMO affiliations, have a higher proportion of patients in HMOs, write more prescriptions across all therapeutic categories, see a higher number of patients, receive more free samples from the sales reps, have more rep intensity in their offices, and allow longer visits by sales reps.

This model has novel implications for drug manufacturers on the effect of time‐in‐the‐market. Accordingly, new drug makers are well‐advised to wait until a drug gets established in the community for it to be prescribed more heavily by specialists and target physicians in solo practice and newer physicians to speed up the adoption process. Furthermore, for newer drugs traditional forms of detailing via a live sales rep are not as effective as for older more established drugs – the new‐drug manufacturer can try other means such as e‐detailing, social media, direct‐to‐consumer advertising, and word‐of‐mouth/mouse to initiate market share.

A key objective of the 5th Annual Pharmaceutical Congress “Marketing ROI for Pharma” conference was to illustrate how in the midst of a very turbulent environment, and with higher demand for pharmaceutical marketers to deliver bigger profits from increasingly smaller promotional budgets, there are a few critical decision areas that, if addressed appropriately, can help to deliver better return on investment (ROI). This commentary paper aims to provide a summary of what was discussed.

Given access to the conference presenters' original materials, the authors condensed the presentations into a summary article with reference to some recent academic work in the area.

The article summarises the presentations of a number of European pharmaceutical industry practitioners, healthcare professionals and government policy personnel in their assessments of the turbulent European pharmaceutical industry environment and the challenges associated with optimising ROI from promotional spending.

The entire paper summarises recent industry practice in Europe regarding how to optimise pharmaceutical ROI with respect to marketing activities and provides actual examples of how to do this.

Primarily targeting pharmaceutical industry practitioners, this paper provides a timely and thorough resource for those industry personnel charged with the mission of maximizing pharmaceutical marketing ROI.

Pharmaceutical sales representatives (PSRs) have been shown to influence the prescribing patterns of physicians. Some of the blame has been shifted from physicians to PSRs due to perceived inadequacies in PSRs' education and certification. The purpose of this paper is to review the literature regarding the current certification requirements for PSRs, motivation for nationally standardized certification and the controversy surrounding pharmaceutical detailing impact on physicians' prescribing behavior.

Articles related to certification for PSRs were identified via searches of PubMed and IPA from inception to March 2011. Search terms included PSRs, PSRs certification, PSRs registration, PSRs education, and PSRs requirements. Articles describing the roles and responsibilities of PSRs, physician and public perception of PSRs, certification processes, and the future of PSRs' roles were included. An internet search was also performed to identify articles in the lay press related to this topic.

This paper shows that the certification for PSRs may become necessary, or even required, to help ensure that the prescribing patterns of physicians are not negatively affected due to false information coming from the PSRs. Therefore, ensuring that PSRs are well certified can lead to better health outcomes for patients. Although pharmaceutical companies do not require certification to gain employment as a sales representative, the certification provides a good knowledge base and insight into the industry.

The paper shows that appropriate training and certification of PSRs may be on the rise for this career path.

Scholars have rarely applied an embodied perspective when studying hospitality experiences. They have given even less attention to methodological considerations. This paper aims to introduce Zaltman’s Metaphor elicitation Technique (ZMET) to explore various domains of the embodied experience.

In demonstrating the applicability of the ZMET procedure to understanding embodied hospitality experiences, the researchers present a study of emotional encounters that involve the dining experiences of Chinese tourists with Western cuisine. The focus of the paper is on data collection, i.e. detailing the step-wise procedures of ZMET that have received minimal scholarly attention.

Through the medium of this empirical study, the ZMET example uncovers deep metaphors and answers previously unanswered questions about embodied experiences. The detailed information and nuanced insights that are generated through this ZMET application offer the prospect of enhanced understanding of the hospitality experience.

This investigation contributes an innovative research method to the embodied experience in the hospitality and tourism context.

The purpose of this paper is to reflect on the development and progression of the International Journal of Pharmaceutical and Healthcare Marketing and include comments on its future direction.

The paper takes the approach of an essay format.

The journal has published key papers in pharmaceutical and healthcare research and continues to develop an interdisciplinary character with contributions from scholarly and practice‐oriented sources.

The paper provides a contemporary appraisal of the status and positioning of the journal.

This paper aims to offer a schema for carrying out a comprehensive training needs assessment (TNA) of medical representatives. The schema answers commonly posed questions, the journalistic six.

A sample of 292 medical representatives (trainees) and 60 training/sales managers (trainers) from 32 pharmaceutical organizations of Pakistan was surveyed. The study attempted to answer the why, what, when, and where aspects of TNA by using correlation and two independent samples t‐test. Who‐ and how‐related aspects were analyzed using descriptive statistics.

The results reveal that the perspectives of trainers and trainees are fully and partially consistent with each other on competency‐based TNA (why), and TNA inputs and TNA products/outcomes (what) respectively. However, a significant difference is found befallen TNA time‐line (when) and TNA situate (where). The results related to TNA decision makers (who), and TNA mechanisms (how) reveal a range of options.

Reliance on data elicited with one shot can border the issue of generalization. Therefore, to compensate this, the study design is explained in fair detail.

The study identifies the gap between the existing literature on the journalistic six on TNA and the perceptions of the study participants on prevailing practices. To fill this gap, the study offers a framework to the pharmaceutical organizations for conducting a comprehensive TNA of their medical representatives.

The proposed schema reveals a set of six coherent areas to be considered for conducting a comprehensive TNA.